iOmx is generating a pipeline of proprietary drug candidates against its novel immune-oncology programs. Leveraging its systematic approach to identify novel checkpoint modulators directly on tumor samples using the iOTargTM platform, iOmx is unveiling organ-specific tumor evasion strategies to develop next-generation of targeted cancer immunotherapies that have monotherapy potential. The Company plans to establish clinical proof-of-concept for select drug candidates.

To learn more about potential partnering opportunities, please contact us at: info@iomx.com

Program Target and Modality Indications Discovery Lead ID Lead Optimization IND Enabling Clinical Ph I
IMT-07 SIK3 Small molecule kinase inhibitor Solid tumors
IMT-NN Undisclosed Monoclonal antibody Solid tumors
Discovery Programs Undisclosed Monoclonal antibodies Solid tumors